A 0 1 0 1 O
QT 2 4 2 4 B-clinical_variable
interval 5 13 5 13 I-clinical_variable
corrected 14 23 14 23 O
for 24 27 24 27 O
heart 28 33 28 33 O
rate 34 38 34 38 O
using 39 44 39 44 O
the 45 48 45 48 O
Bazett 49 55 49 55 B-clinical_variable
's 55 57 55 57 I-clinical_variable
formula 58 65 58 65 I-clinical_variable
QTcB 66 70 66 70 I-clinical_variable
> 71 72 71 72 O
= 72 73 72 73 O
480 74 77 74 77 B-lower_bound
msec 78 82 78 82 I-lower_bound
on 83 85 83 85 O
screening 86 95 86 95 O
electrocardiography 96 115 96 115 B-clinical_variable
( 116 117 116 117 I-clinical_variable
ECG 117 120 117 120 I-clinical_variable
) 120 121 120 121 I-clinical_variable

A 0 1 122 123 O
history 2 9 124 131 O
of 10 12 132 134 O
glucose-6 13 22 135 144 B-chronic_disease
- 22 23 144 145 I-chronic_disease
phosphate 23 32 145 154 I-chronic_disease
dehydrogenase 33 46 155 168 I-chronic_disease
( 47 48 169 170 I-chronic_disease
G6PD 48 52 170 174 I-chronic_disease
) 52 53 174 175 I-chronic_disease
deficiency 54 64 176 186 I-chronic_disease

Able 0 4 187 191 O
to 5 7 192 194 O
swallow 8 15 195 202 O
and 16 19 203 206 O
retain 20 26 207 213 O
oral 27 31 214 218 B-treatment
medication 32 42 219 229 I-treatment
and 43 46 230 233 O
must 47 51 234 238 O
not 52 55 239 242 O
have 56 60 243 247 O
any 61 64 248 251 O
clinically 65 75 252 262 O
significant 76 87 263 274 O
gastrointestinal 88 104 275 291 B-chronic_disease
abnormalities 105 118 292 305 I-chronic_disease
that 119 123 306 310 O
may 124 127 311 314 O
alter 128 133 315 320 O
absorption 134 144 321 331 O
such 145 149 332 336 O
as 150 152 337 339 O
malabsorption 153 166 340 353 B-chronic_disease
syndrome 167 175 354 362 I-chronic_disease
or 176 178 363 365 O
major 179 184 366 371 B-treatment
resection 185 194 372 381 I-treatment
of 195 197 382 384 O
the 198 201 385 388 O
stomach 202 209 389 396 O
or 210 212 397 399 O
bowels 213 219 400 406 O

Abnormal 0 8 407 415 B-clinical_variable
cardiac 9 16 416 423 I-clinical_variable
valve 17 22 424 429 I-clinical_variable
morphology 23 33 430 440 I-clinical_variable
( 34 35 441 442 O
> 35 36 442 443 O
= 36 37 443 444 O
grade 38 43 445 450 B-lower_bound
2 44 45 451 452 I-lower_bound
) 45 46 452 453 O
documented 47 57 454 464 O
by 58 60 465 467 O
echocardiogram 61 75 468 482 B-treatment
( 76 77 483 484 O
subjects 77 85 484 492 O
with 86 90 493 497 O
grade 91 96 498 503 O
1 97 98 504 505 O
abnormalities 99 112 506 519 O
[ 113 114 520 521 O
i.e. 114 118 521 525 O
, 118 119 525 526 O
mild 120 124 527 531 O
regurgitation 125 138 532 545 B-chronic_disease
/ 138 139 545 546 O
stenosis 139 147 546 554 B-chronic_disease
] 147 148 554 555 O
can 149 152 556 559 O
be 153 155 560 562 O
entered 156 163 563 570 O
on 164 166 571 573 O
study 167 172 574 579 O
) 172 173 579 580 O
; 173 174 580 581 O
subjects 175 183 582 590 O
with 184 188 591 595 O
moderate 189 197 596 604 O
valvular 198 206 605 613 O
thickening 207 217 614 624 O
should 218 224 625 631 O
not 225 228 632 635 O
be 229 231 636 638 O
entered 232 239 639 646 O
on 240 242 647 649 O
study 243 248 650 655 O

Absolute 0 8 656 664 O
neutrophil 9 19 665 675 B-clinical_variable
count 20 25 676 681 I-clinical_variable
> 26 27 682 683 O
= 27 28 683 684 O
1 29 30 685 686 B-lower_bound
x 31 32 687 688 I-lower_bound
10 33 35 689 691 I-lower_bound
^ 35 36 691 692 I-lower_bound
9 36 37 692 693 I-lower_bound
/ 37 38 693 694 I-lower_bound
L 38 39 694 695 I-lower_bound

Antibiotics 0 11 696 707 B-treatment
: 11 12 707 708 O
clarithromycin 13 27 709 723 B-treatment
, 27 28 723 724 O
telithromycin 29 42 725 738 B-treatment
, 42 43 738 739 O
troleandomycin 44 58 740 754 B-treatment

Antibiotics 0 11 755 766 B-treatment
: 11 12 766 767 O
rifamycin 13 22 768 777 B-treatment
class 23 28 778 783 O
agents 29 35 784 790 O
( 36 37 791 792 O
e.g. 37 41 792 796 O
, 41 42 796 797 O
rifampin 43 51 798 806 B-treatment
, 51 52 806 807 O
rifabutin 53 62 808 817 B-treatment
, 62 63 817 818 O
rifapentine 64 75 819 830 B-treatment
) 75 76 830 831 O

Anticoagulants 0 14 832 846 B-treatment
or 15 17 847 849 O
antiplatelet 18 30 850 862 B-treatment
agents 31 37 863 869 I-treatment
except 38 44 870 876 O
for 45 48 877 880 O
low 49 52 881 884 O
- 52 53 884 885 O
dose 53 57 885 889 O
, 57 58 889 890 O
81 59 61 891 893 O
mg 62 64 894 896 O
aspirin 65 72 897 904 B-treatment

Anticonvulsants 0 15 905 920 B-treatment
: 15 16 920 921 O
carbamazepine 17 30 922 935 B-treatment
, 30 31 935 936 O
oxcarbazepine 32 45 937 950 B-treatment
, 45 46 950 951 O
phenobarbital 47 60 952 965 B-treatment
, 60 61 965 966 O
phenytoin 62 71 967 976 B-treatment
, 71 72 976 977 O
s 73 74 978 979 O
- 74 75 979 980 O
mephenytoin 75 86 980 991 B-treatment

Antidepressants 0 15 992 1007 B-treatment
: 15 16 1007 1008 O
nefazodone 17 27 1009 1019 B-treatment

Antifungals 0 11 1020 1031 B-treatment
: 11 12 1031 1032 O
itraconazole 13 25 1033 1045 B-treatment
, 25 26 1045 1046 O
ketoconazole 27 39 1047 1059 B-treatment
, 39 40 1059 1060 O
posaconazole 41 53 1061 1073 B-treatment
, 53 54 1073 1074 O
voriconazole 55 67 1075 1087 B-treatment

Antiretroviral 0 14 1088 1102 B-treatment
: 14 15 1102 1103 O
ritonavir 16 25 1104 1113 B-treatment
, 25 26 1113 1114 O
saquinavir 27 37 1115 1125 B-treatment
, 37 38 1125 1126 O
atazanavir 39 49 1127 1137 B-treatment

Aspartate 0 9 1138 1147 B-clinical_variable
aminotransferase 10 26 1148 1164 I-clinical_variable
( 27 28 1165 1166 I-clinical_variable
AST 28 31 1166 1169 I-clinical_variable
) 31 32 1169 1170 I-clinical_variable
( 33 34 1171 1172 O
serum 34 39 1172 1177 B-clinical_variable
glutamic 40 48 1178 1186 I-clinical_variable
oxaloacetic 49 60 1187 1198 I-clinical_variable
transaminase 61 73 1199 1211 I-clinical_variable
[ 74 75 1212 1213 I-clinical_variable
SGOT])/alanine 75 89 1213 1227 I-clinical_variable
aminotransferase 90 106 1228 1244 I-clinical_variable
( 107 108 1245 1246 I-clinical_variable
ALT 108 111 1246 1249 I-clinical_variable
) 111 112 1249 1250 I-clinical_variable
( 113 114 1251 1252 O
serum 114 119 1252 1257 B-clinical_variable
glutamate 120 129 1258 1267 I-clinical_variable
pyruvate 130 138 1268 1276 I-clinical_variable
transaminase 139 151 1277 1289 I-clinical_variable
[ 152 153 1290 1291 I-clinical_variable
SGPT 153 157 1291 1295 I-clinical_variable
] 157 158 1295 1296 I-clinical_variable
) 158 159 1296 1297 O
= 160 161 1298 1299 O
< 161 162 1299 1300 O
2.5 163 166 1301 1304 B-upper_bound
x 167 168 1305 1306 I-upper_bound
institutional 169 182 1307 1320 I-upper_bound
upper 183 188 1321 1326 I-upper_bound
limit 189 194 1327 1332 I-upper_bound
of 195 197 1333 1335 I-upper_bound
normal 198 204 1336 1342 I-upper_bound

Because 0 7 1343 1350 O
the 8 11 1351 1354 O
composition 12 23 1355 1366 O
, 23 24 1366 1367 O
pharmacokinetics 25 41 1368 1384 O
( 42 43 1385 1386 O
PK 43 45 1386 1388 O
) 45 46 1388 1389 O
, 46 47 1389 1390 O
and 48 51 1391 1394 O
metabolism 52 62 1395 1405 O
of 63 65 1406 1408 O
many 66 70 1409 1413 O
herbal 71 77 1414 1420 B-treatment
supplements 78 89 1421 1432 I-treatment
are 90 93 1433 1436 O
unknown 94 101 1437 1444 O
, 101 102 1444 1445 O
the 103 106 1446 1449 O
concurrent 107 117 1450 1460 O
use 118 121 1461 1464 O
of 122 124 1465 1467 O
all 125 128 1468 1471 O
herbal 129 135 1472 1478 O
supplements 136 147 1479 1490 O
is 148 150 1491 1493 O
prohibited 151 161 1494 1504 O
during 162 168 1505 1511 O
the 169 172 1512 1515 O
study 173 178 1516 1521 O
( 179 180 1522 1523 O
including 180 189 1523 1532 O
, 189 190 1532 1533 O
but 191 194 1534 1537 O
not 195 198 1538 1541 O
limited 199 206 1542 1549 O
to 207 209 1550 1552 O
, 209 210 1552 1553 O
St. 211 214 1554 1557 B-treatment
John 215 219 1558 1562 I-treatment
's 219 221 1562 1564 I-treatment
wort 222 226 1565 1569 I-treatment
, 226 227 1569 1570 O
kava 228 232 1571 1575 B-treatment
, 232 233 1575 1576 O
ephedra 234 241 1577 1584 B-treatment
[ 242 243 1585 1586 I-treatment
ma 243 245 1586 1588 I-treatment
huang 246 251 1589 1594 I-treatment
] 251 252 1594 1595 I-treatment
, 252 253 1595 1596 O
ginkgo 254 260 1597 1603 B-treatment
biloba 261 267 1604 1610 I-treatment
, 267 268 1610 1611 O
dehydroepiandrosterone 269 291 1612 1634 B-treatment
[ 292 293 1635 1636 I-treatment
DHEA 293 297 1636 1640 I-treatment
] 297 298 1640 1641 I-treatment
, 298 299 1641 1642 O
yohimbe 300 307 1643 1650 B-treatment
, 307 308 1650 1651 O
saw 309 312 1652 1655 B-treatment
palmetto 313 321 1656 1664 I-treatment
, 321 322 1664 1665 O
or 323 325 1666 1668 O
ginseng 326 333 1669 1676 B-treatment
) 333 334 1676 1677 O

Concurrent 0 10 1678 1688 O
treatment 11 20 1689 1698 B-treatment
with 21 25 1699 1703 I-treatment
bisphosphonates 26 41 1704 1719 I-treatment
is 42 44 1720 1722 O
permitted 45 54 1723 1732 O
; 54 55 1732 1733 O
however 56 63 1734 1741 O
, 63 64 1741 1742 O
treatment 65 74 1743 1752 O
must 75 79 1753 1757 O
be 80 82 1758 1760 O
initiated 83 92 1761 1770 O
prior 93 98 1771 1776 O
to 99 101 1777 1779 O
the 102 105 1780 1783 O
first 106 111 1784 1789 O
dose 112 116 1790 1794 O
of 117 119 1795 1797 O
study 120 125 1798 1803 O
therapy 126 133 1804 1811 B-treatment
; 133 134 1811 1812 O
prophylactic 135 147 1813 1825 B-treatment
use 148 151 1826 1829 O
of 152 154 1830 1832 O
bisphosphonates 155 170 1833 1848 O
in 171 173 1849 1851 O
patients 174 182 1852 1860 O
without 183 190 1861 1868 O
bone 191 195 1869 1873 O
disease 196 203 1874 1881 O
is 204 206 1882 1884 O
not 207 210 1885 1888 O
permitted 211 220 1889 1898 O
, 220 221 1898 1899 O
except 222 228 1900 1906 O
for 229 232 1907 1910 O
the 233 236 1911 1914 O
treatment 237 246 1915 1924 B-treatment
of 247 249 1925 1927 I-treatment
osteoporosis 250 262 1928 1940 I-treatment

Current 0 7 1941 1948 O
use 8 11 1949 1952 O
of 12 14 1953 1955 O
a 15 16 1956 1957 O
prohibited 17 27 1958 1968 O
medication 28 38 1969 1979 B-treatment
; 38 39 1979 1980 O
the 40 43 1981 1984 O
following 44 53 1985 1994 O
medications 54 65 1995 2006 B-treatment
or 66 68 2007 2009 O
non 69 72 2010 2013 B-treatment
- 72 73 2013 2014 I-treatment
drug 73 77 2014 2018 I-treatment
therapies 78 87 2019 2028 I-treatment
are 88 91 2029 2032 O
prohibited 92 102 2033 2043 O

Due 0 3 2044 2047 O
to 4 6 2048 2050 O
the 7 10 2051 2054 O
expected 11 19 2055 2063 O
dose 20 24 2064 2068 O
- 24 25 2068 2069 O
limiting 25 33 2069 2077 O
toxicity 34 42 2078 2086 O
of 43 45 2087 2089 O
thrombocytopenia 46 62 2090 2106 B-chronic_disease
, 62 63 2106 2107 O
the 64 67 2108 2111 O
following 68 77 2112 2121 O
concomitant 78 89 2122 2133 B-treatment
medications 90 101 2134 2145 I-treatment
are 102 105 2146 2149 O
not 106 109 2150 2153 O
allowed 110 117 2154 2161 O
during 118 124 2162 2168 O
navitoclax 125 135 2169 2179 B-treatment
administration 136 150 2180 2194 O
: 150 151 2194 2195 O
clopidogrel 152 163 2196 2207 B-treatment
, 163 164 2207 2208 O
ibuprofen 165 174 2209 2218 B-treatment
, 174 175 2218 2219 O
tirofiban 176 185 2220 2229 B-treatment
, 185 186 2229 2230 O
warfarin 187 195 2231 2239 B-treatment
, 195 196 2239 2240 O
and 197 200 2241 2244 O
other 201 206 2245 2250 O
anticoagulants 207 221 2251 2265 B-treatment
, 221 222 2265 2266 O
drugs 223 228 2267 2272 B-treatment
, 228 229 2272 2273 O
or 230 232 2274 2276 O
herbal 233 239 2277 2283 B-treatment
supplements 240 251 2284 2295 I-treatment
that 252 256 2296 2300 O
affect 257 263 2301 2307 O
platelet 264 272 2308 2316 O
function 273 281 2317 2325 O
are 282 285 2326 2329 O
excluded 286 294 2330 2338 O
, 294 295 2338 2339 O
with 296 300 2340 2344 O
the 301 304 2345 2348 O
exception 305 314 2349 2358 O
of 315 317 2359 2361 O
low 318 321 2362 2365 O
- 321 322 2365 2366 O
dose 322 326 2366 2370 O
anticoagulation 327 342 2371 2386 B-treatment
medications 343 354 2387 2398 I-treatment
( 355 356 2399 2400 O
such 356 360 2400 2404 O
as 361 363 2405 2407 O
heparin 364 371 2408 2415 B-treatment
) 371 372 2415 2416 O
that 373 377 2417 2421 O
are 378 381 2422 2425 O
used 382 386 2426 2430 O
to 387 389 2431 2433 O
maintain 390 398 2434 2442 O
the 399 402 2443 2446 O
patency 403 410 2447 2454 O
of 411 413 2455 2457 O
a 414 415 2458 2459 O
central 416 423 2460 2467 B-treatment
intravenous 424 435 2468 2479 I-treatment
catheter 436 444 2480 2488 I-treatment
; 444 445 2488 2489 O
aspirin 446 453 2490 2497 B-treatment
will 454 458 2498 2502 O
not 459 462 2503 2506 O
be 463 465 2507 2509 O
allowed 466 473 2510 2517 O
within 474 480 2518 2524 O
7 481 482 2525 2526 B-upper_bound
days 483 487 2527 2531 I-upper_bound
prior 488 493 2532 2537 I-upper_bound
to 494 496 2538 2540 O
the 497 500 2541 2544 O
first 501 506 2545 2550 O
dose 507 511 2551 2555 O
of 512 514 2556 2558 O
navitoclax 515 525 2559 2569 O
or 526 528 2570 2572 O
during 529 535 2573 2579 O
navitoclax 536 546 2580 2590 O
administration 547 561 2591 2605 O
; 561 562 2605 2606 O
however 563 570 2607 2614 O
, 570 571 2614 2615 O
subjects 572 580 2616 2624 O
who 581 584 2625 2628 O
have 585 589 2629 2633 O
previously 590 600 2634 2644 O
received 601 609 2645 2653 O
aspirin 610 617 2654 2661 B-treatment
therapy 618 625 2662 2669 I-treatment
for 626 629 2670 2673 O
thrombosis 630 640 2674 2684 B-chronic_disease
prevention 641 651 2685 2695 O
may 652 655 2696 2699 O
resume 656 662 2700 2706 O
a 663 664 2707 2708 O
low 665 668 2709 2712 O
dose 669 673 2713 2717 O
( 674 675 2718 2719 O
i.e. 675 679 2719 2723 O
, 679 680 2723 2724 O
maximum 681 688 2725 2732 O
100 689 692 2733 2736 B-upper_bound
mg 693 695 2737 2739 I-upper_bound
QD 696 698 2740 2742 I-upper_bound
) 698 699 2742 2743 O
of 700 702 2744 2746 O
aspirin 703 710 2747 2754 O
if 711 713 2755 2757 O
platelet 714 722 2758 2766 B-clinical_variable
counts 723 729 2767 2773 I-clinical_variable
are 730 733 2774 2777 O
stable 734 740 2778 2784 O
( 741 742 2785 2786 O
> 742 743 2786 2787 O
= 743 744 2787 2788 O
50,000 745 751 2789 2795 B-lower_bound
/ 751 752 2795 2796 I-lower_bound
mm^3 752 756 2796 2800 I-lower_bound
) 756 757 2800 2801 O
through 758 765 2802 2809 O
6 766 767 2810 2811 B-upper_bound
weeks 768 773 2812 2817 I-upper_bound
of 774 776 2818 2820 O
navitoclax 777 787 2821 2831 O
administration 788 802 2832 2846 O
; 802 803 2846 2847 O
all 804 807 2848 2851 O
decisions 808 817 2852 2861 O
regarding 818 827 2862 2871 O
treatment 828 837 2872 2881 B-treatment
with 838 842 2882 2886 I-treatment
aspirin 843 850 2887 2894 I-treatment
therapy 851 858 2895 2902 I-treatment
will 859 863 2903 2907 O
be 864 866 2908 2910 O
determined 867 877 2911 2921 O
by 878 880 2922 2924 O
the 881 884 2925 2928 O
investigator 885 897 2929 2941 O
in 898 900 2942 2944 O
conjunction 901 912 2945 2956 O
with 913 917 2957 2961 O
the 918 921 2962 2965 O
medical 922 929 2966 2973 O
monitor 930 937 2974 2981 O

Eastern 0 7 2982 2989 B-clinical_variable
Cooperative 8 19 2990 3001 I-clinical_variable
Oncology 20 28 3002 3010 I-clinical_variable
Group 29 34 3011 3016 I-clinical_variable
( 35 36 3017 3018 I-clinical_variable
ECOG 36 40 3018 3022 I-clinical_variable
) 40 41 3022 3023 I-clinical_variable
performance 42 53 3024 3035 I-clinical_variable
status 54 60 3036 3042 I-clinical_variable
= 61 62 3043 3044 O
< 62 63 3044 3045 O
1 64 65 3046 3047 B-upper_bound
( 66 67 3048 3049 O
Karnofsky 67 76 3049 3058 B-clinical_variable
> 77 78 3059 3060 O
= 78 79 3060 3061 O
70 80 82 3062 3064 B-lower_bound
% 82 83 3064 3065 I-lower_bound
) 83 84 3065 3066 O

Hemoglobin 0 10 3067 3077 B-clinical_variable
> 11 12 3078 3079 O
= 12 13 3079 3080 O
9 14 15 3081 3082 B-lower_bound
g 16 17 3083 3084 I-lower_bound
/ 17 18 3084 3085 I-lower_bound
dl 18 20 3085 3087 I-lower_bound
( 21 22 3088 3089 O
patients 22 30 3089 3097 O
may 31 34 3098 3101 O
be 35 37 3102 3104 O
transfused 38 48 3105 3115 O
to 49 51 3116 3118 O
this 52 56 3119 3123 O
level 57 62 3124 3129 O
) 62 63 3129 3130 O

History 0 7 3131 3138 O
of 8 10 3139 3141 O
RVO 11 14 3142 3145 B-chronic_disease
or 15 17 3146 3148 O
CSR 18 21 3149 3152 B-chronic_disease
, 21 22 3152 3153 O
or 23 25 3154 3156 O
predisposing 26 38 3157 3169 O
factors 39 46 3170 3177 O
to 47 49 3178 3180 O
RVO 50 53 3181 3184 O
or 54 56 3185 3187 O
CSR 57 60 3188 3191 O
( 61 62 3192 3193 O
e.g. 62 66 3193 3197 O
, 66 67 3197 3198 O
uncontrolled 68 80 3199 3211 O
glaucoma 81 89 3212 3220 B-chronic_disease
or 90 92 3221 3223 O
ocular 93 99 3224 3230 B-chronic_disease
hypertension 100 112 3231 3243 I-chronic_disease
, 112 113 3243 3244 O
uncontrolled 114 126 3245 3257 O
systemic 127 135 3258 3266 B-chronic_disease
disease 136 143 3267 3274 I-chronic_disease
such 144 148 3275 3279 O
as 149 151 3280 3282 O
hypertension 152 164 3283 3295 O
, 164 165 3295 3296 O
diabetes 166 174 3297 3305 B-chronic_disease
mellitus 175 183 3306 3314 I-chronic_disease
, 183 184 3314 3315 O
or 185 187 3316 3318 O
history 188 195 3319 3326 O
of 196 198 3327 3329 O
hyperviscosity 199 213 3330 3344 B-chronic_disease
or 214 216 3345 3347 O
hypercoagulability 217 235 3348 3366 B-chronic_disease
syndromes 236 245 3367 3376 O
) 245 246 3376 3377 O

History 0 7 3378 3385 O
of 8 10 3386 3388 O
acute 11 16 3389 3394 B-chronic_disease
coronary 17 25 3395 3403 I-chronic_disease
syndromes 26 35 3404 3413 I-chronic_disease
( 36 37 3414 3415 O
including 37 46 3415 3424 O
myocardial 47 57 3425 3435 B-chronic_disease
infarction 58 68 3436 3446 I-chronic_disease
and 69 72 3447 3450 O
unstable 73 81 3451 3459 B-chronic_disease
angina 82 88 3460 3466 I-chronic_disease
) 88 89 3466 3467 O
, 89 90 3467 3468 O
coronary 91 99 3469 3477 B-treatment
angioplasty 100 111 3478 3489 I-treatment
, 111 112 3489 3490 O
or 113 115 3491 3493 O
stenting 116 124 3494 3502 B-treatment
within 125 131 3503 3509 O
6 132 133 3510 3511 B-upper_bound
months 134 140 3512 3518 I-upper_bound
prior 141 146 3519 3524 I-upper_bound
to 147 149 3525 3527 O
randomization 150 163 3528 3541 B-treatment

History 0 7 3542 3549 O
of 8 10 3550 3552 O
allergic 11 19 3553 3561 O
reactions 20 29 3562 3571 O
attributed 30 40 3572 3582 O
to 41 43 3583 3585 O
compounds 44 53 3586 3595 O
of 54 56 3596 3598 O
similar 57 64 3599 3606 O
chemical 65 73 3607 3615 O
or 74 76 3616 3618 O
biologic 77 85 3619 3627 O
composition 86 97 3628 3639 O
to 98 100 3640 3642 O
navitoclax 101 111 3643 3653 B-allergy_name
, 111 112 3653 3654 O
dabrafenib 113 123 3655 3665 B-allergy_name
, 123 124 3665 3666 O
or 125 127 3667 3669 O
trametinib 128 138 3670 3680 B-allergy_name
, 138 139 3680 3681 O
or 140 142 3682 3684 O
excipients 143 153 3685 3695 O
or 154 156 3696 3698 O
to 157 159 3699 3701 O
dimethyl 160 168 3702 3710 B-allergy_name
sulfoxide 169 178 3711 3720 I-allergy_name
( 179 180 3721 3722 I-allergy_name
DMSO 180 184 3722 3726 I-allergy_name
) 184 185 3726 3727 I-allergy_name

History 0 7 3728 3735 O
of 8 10 3736 3738 O
another 11 18 3739 3746 O
malignancy 19 29 3747 3757 B-cancer
; 29 30 3757 3758 O
exception 31 40 3759 3768 O
: 40 41 3768 3769 O
patients 42 50 3770 3778 O
who 51 54 3779 3782 O
have 55 59 3783 3787 O
been 60 64 3788 3792 O
disease 65 72 3793 3800 O
- 72 73 3800 3801 O
free 73 77 3801 3805 O
for 78 81 3806 3809 O
3 82 83 3810 3811 B-lower_bound
years 84 89 3812 3817 O
( 90 91 3818 3819 O
depending 91 100 3819 3828 O
upon 101 105 3829 3833 O
tumor 106 111 3834 3839 B-cancer
type 112 116 3840 3844 O
studied 117 124 3845 3852 O
or 125 127 3853 3855 O
clinical 128 136 3856 3864 O
setting 137 144 3865 3872 O
, 144 145 3872 3873 O
3 146 147 3874 3875 O
or 148 150 3876 3878 O
5 151 152 3879 3880 O
years 153 158 3881 3886 O
can 159 162 3887 3890 O
be 163 165 3891 3893 O
used 166 170 3894 3898 O
; 170 171 3898 3899 O
e.g. 172 176 3900 3904 O
, 176 177 3904 3905 O
for 178 181 3906 3909 O
advanced 182 190 3910 3918 B-cancer
melanoma 191 199 3919 3927 I-cancer
and 200 203 3928 3931 O
pancreatic 204 214 3932 3942 O
studies 215 222 3943 3950 O
3 223 224 3951 3952 O
years 225 230 3953 3958 O
is 231 233 3959 3961 O
more 234 238 3962 3966 O
appropriate 239 250 3967 3978 O
due 251 254 3979 3982 O
to 255 257 3983 3985 O
aggressiveness 258 272 3986 4000 O
of 273 275 4001 4003 O
the 276 279 4004 4007 O
disease 280 287 4008 4015 O
, 287 288 4015 4016 O
while 289 294 4017 4022 O
5 295 296 4023 4024 O
years 297 302 4025 4030 O
can 303 306 4031 4034 O
be 307 309 4035 4037 O
more 310 314 4038 4042 O
appropriate 315 326 4043 4054 O
for 327 330 4055 4058 O
prostate 331 339 4059 4067 B-cancer
or 340 342 4068 4070 O
ovarian 343 350 4071 4078 B-cancer
cancer 351 357 4079 4085 I-cancer
or 358 360 4086 4088 O
adjuvant 361 369 4089 4097 B-treatment
setting 370 377 4098 4105 I-treatment
when 378 382 4106 4110 O
life 383 387 4111 4115 O
expectancy 388 398 4116 4126 O
is 399 401 4127 4129 O
longer 402 408 4130 4136 O
) 408 409 4136 4137 O
, 409 410 4137 4138 O
or 411 413 4139 4141 O
patients 414 422 4142 4150 O
with 423 427 4151 4155 O
a 428 429 4156 4157 O
history 430 437 4158 4165 O
of 438 440 4166 4168 O
completely 441 451 4169 4179 O
resected 452 460 4180 4188 O
non 461 464 4189 4192 B-cancer
- 464 465 4192 4193 I-cancer
melanoma 465 473 4193 4201 I-cancer
skin 474 478 4202 4206 I-cancer
cancer 479 485 4207 4213 I-cancer
and/or 486 492 4214 4220 O
patients 493 501 4221 4229 O
with 502 506 4230 4234 O
indolent 507 515 4235 4243 O
secondary 516 525 4244 4253 B-cancer
malignancies 526 538 4254 4266 I-cancer
, 538 539 4266 4267 O
are 540 543 4268 4271 O
eligible 544 552 4272 4280 O
; 552 553 4280 4281 O
consult 554 561 4282 4289 O
the 562 565 4290 4293 O
CTEP 566 570 4294 4298 O
medical 571 578 4299 4306 O
monitor 579 586 4307 4314 O
if 587 589 4315 4317 O
unsure 590 596 4318 4324 O
whether 597 604 4325 4332 O
second 605 611 4333 4339 B-cancer
malignancies 612 624 4340 4352 I-cancer
meet 625 629 4353 4357 O
the 630 633 4358 4361 O
requirements 634 646 4362 4374 O
specified 647 656 4375 4384 O
above 657 662 4385 4390 O
; 662 663 4390 4391 O
exception 664 673 4392 4401 O
: 673 674 4401 4402 O
patients 675 683 4403 4411 O
with 684 688 4412 4416 O
history 689 696 4417 4424 O
of 697 699 4425 4427 O
RAS 700 703 4428 4431 O
mutation 704 712 4432 4440 O
- 712 713 4440 4441 O
positive 713 721 4441 4449 O
tumors 722 728 4450 4456 B-cancer
are 729 732 4457 4460 O
not 733 736 4461 4464 O
eligible 737 745 4465 4473 O
regardless 746 756 4474 4484 O
of 757 759 4485 4487 O
interval 760 768 4488 4496 O
from 769 773 4497 4501 O
the 774 777 4502 4505 O
current 778 785 4506 4513 O
study 786 791 4514 4519 O
; 791 792 4519 4520 O
prospective 793 804 4521 4532 O
RAS 805 808 4533 4536 O
testing 809 816 4537 4544 O
is 817 819 4545 4547 O
not 820 823 4548 4551 O
required 824 832 4552 4560 O
; 832 833 4560 4561 O
however 834 841 4562 4569 O
, 841 842 4569 4570 O
if 843 845 4571 4573 O
the 846 849 4574 4577 O
results 850 857 4578 4585 O
of 858 860 4586 4588 O
previous 861 869 4589 4597 O
RAS 870 873 4598 4601 O
testing 874 881 4602 4609 O
are 882 885 4610 4613 O
known 886 891 4614 4619 O
, 891 892 4619 4620 O
they 893 897 4621 4625 O
must 898 902 4626 4630 O
be 903 905 4631 4633 O
used 906 910 4634 4638 O
in 911 913 4639 4641 O
assessing 914 923 4642 4651 O
eligibility 924 935 4652 4663 O

History 0 7 4664 4671 O
of 8 10 4672 4674 O
interstitial 11 23 4675 4687 O
lung 24 28 4688 4692 B-chronic_disease
disease 29 36 4693 4700 I-chronic_disease
or 37 39 4701 4703 O
pneumonitis 40 51 4704 4715 B-chronic_disease

History 0 7 4716 4723 O
or 8 10 4724 4726 O
current 11 18 4727 4734 O
evidence 19 27 4735 4743 O
/ 27 28 4743 4744 O
risk 28 32 4744 4748 O
of 33 35 4749 4751 O
retinal 36 43 4752 4759 B-chronic_disease
vein 44 48 4760 4764 I-chronic_disease
occlusion 49 58 4765 4774 I-chronic_disease
( 59 60 4775 4776 I-chronic_disease
RVO 60 63 4776 4779 I-chronic_disease
) 63 64 4779 4780 I-chronic_disease
or 65 67 4781 4783 O
central 68 75 4784 4791 B-chronic_disease
serous 76 82 4792 4798 I-chronic_disease
retinopathy 83 94 4799 4810 I-chronic_disease
( 95 96 4811 4812 I-chronic_disease
CSR 96 99 4812 4815 I-chronic_disease
) 99 100 4815 4816 I-chronic_disease

History 0 7 4817 4824 O
or 8 10 4825 4827 O
evidence 11 19 4828 4836 O
of 20 22 4837 4839 O
current 23 30 4840 4847 O
> 31 32 4848 4849 O
= 32 33 4849 4850 O
class 34 39 4851 4856 B-lower_bound
II 40 42 4857 4859 I-lower_bound
congestive 43 53 4860 4870 B-chronic_disease
heart 54 59 4871 4876 I-chronic_disease
failure 60 67 4877 4884 I-chronic_disease
as 68 70 4885 4887 O
defined 71 78 4888 4895 O
by 79 81 4896 4898 O
the 82 85 4899 4902 O
New 86 89 4903 4906 B-clinical_variable
York 90 94 4907 4911 I-clinical_variable
Heart 95 100 4912 4917 I-clinical_variable
Association 101 112 4918 4929 I-clinical_variable
( 113 114 4930 4931 I-clinical_variable
NYHA 114 118 4931 4935 I-clinical_variable
) 118 119 4935 4936 I-clinical_variable
functional 120 130 4937 4947 O
classification 131 145 4948 4962 O
system 146 152 4963 4969 O

History 0 7 4970 4977 O
or 8 10 4978 4980 O
evidence 11 19 4981 4989 O
of 20 22 4990 4992 O
current 23 30 4993 5000 O
clinically 31 41 5001 5011 O
significant 42 53 5012 5023 O
uncontrolled 54 66 5024 5036 O
arrhythmias 67 78 5037 5048 B-chronic_disease
( 79 80 5049 5050 O
exception 80 89 5050 5059 O
: 89 90 5059 5060 O
patients 91 99 5061 5069 O
with 100 104 5070 5074 O
controlled 105 115 5075 5085 O
atrial 116 122 5086 5092 B-chronic_disease
fibrillation 123 135 5093 5105 I-chronic_disease
for 136 139 5106 5109 O
> 140 141 5110 5111 O
30 142 144 5112 5114 B-lower_bound
days 145 149 5115 5119 I-lower_bound
prior 150 155 5120 5125 I-lower_bound
to 156 158 5126 5128 O
randomization 159 172 5129 5142 O
are 173 176 5143 5146 O
eligible 177 185 5147 5155 O
) 185 186 5155 5156 O

Human 0 5 5157 5162 B-chronic_disease
immunodeficiency 6 22 5163 5179 I-chronic_disease
virus 23 28 5180 5185 I-chronic_disease
( 29 30 5186 5187 I-chronic_disease
HIV)-positive 30 43 5187 5200 I-chronic_disease
patients 44 52 5201 5209 O
on 53 55 5210 5212 O
combination 56 67 5213 5224 B-treatment
antiretroviral 68 82 5225 5239 I-treatment
therapy 83 90 5240 5247 I-treatment
that 91 95 5248 5252 O
predict 96 103 5253 5260 O
to 104 106 5261 5263 O
interact 107 115 5264 5272 O
with 116 120 5273 5277 O
any 121 124 5278 5281 O
of 125 127 5282 5284 O
the 128 131 5285 5288 O
study 132 137 5289 5294 B-treatment
drugs 138 143 5295 5300 I-treatment
are 144 147 5301 5304 O
ineligible 148 158 5305 5315 O
because 159 166 5316 5323 O
of 167 169 5324 5326 O
the 170 173 5327 5330 O
potential 174 183 5331 5340 O
for 184 187 5341 5344 O
pharmacokinetic 188 203 5345 5360 O
interactions 204 216 5361 5373 O
with 217 221 5374 5378 O
the 222 225 5379 5382 O
study 226 231 5383 5388 O
drugs 232 237 5389 5394 O
; 237 238 5394 5395 O
appropriate 239 250 5396 5407 O
studies 251 258 5408 5415 O
will 259 263 5416 5420 O
be 264 266 5421 5423 O
undertaken 267 277 5424 5434 O
in 278 280 5435 5437 O
patients 281 289 5438 5446 O
receiving 290 299 5447 5456 O
combination 300 311 5457 5468 O
antiretroviral 312 326 5469 5483 O
therapy 327 334 5484 5491 O
when 335 339 5492 5496 O
indicated 340 349 5497 5506 O
; 349 350 5506 5507 O
it 351 353 5508 5510 O
is 354 356 5511 5513 O
not 357 360 5514 5517 O
necessary 361 370 5518 5527 O
to 371 373 5528 5530 O
conduct 374 381 5531 5538 O
HIV 382 385 5539 5542 O
testing 386 393 5543 5550 O
at 394 396 5551 5553 O
screening 397 406 5554 5563 O
; 406 407 5563 5564 O
patients 408 416 5565 5573 O
who 417 420 5574 5577 O
are 421 424 5578 5581 O
HIV 425 428 5582 5585 O
- 428 429 5585 5586 O
positive 429 437 5586 5594 O
with 438 442 5595 5599 O
undetectable 443 455 5600 5612 O
viral 456 461 5613 5618 O
loads 462 467 5619 5624 O
, 467 468 5624 5625 O
not 469 472 5626 5629 O
on 473 475 5630 5632 O
interacting 476 487 5633 5644 B-treatment
antiretroviral 488 502 5645 5659 I-treatment
therapy 503 510 5660 5667 I-treatment
, 510 511 5667 5668 O
and 512 515 5669 5672 O
have 516 520 5673 5677 O
CD4 521 524 5678 5681 B-clinical_variable
counts 525 531 5682 5688 I-clinical_variable
above 532 537 5689 5694 O
300 538 541 5695 5698 B-lower_bound
/ 541 542 5698 5699 I-lower_bound
mm^3 542 546 5699 5703 I-lower_bound
may 547 550 5704 5707 O
be 551 553 5708 5710 O
eligible 554 562 5711 5719 O
after 563 568 5720 5725 O
discussion 569 579 5726 5736 O
with 580 584 5737 5741 O
the 585 588 5742 5745 O
principal 589 598 5746 5755 O
investigator 599 611 5756 5768 O

Hyperlipidemia 0 14 5769 5783 B-chronic_disease
: 14 15 5783 5784 O
gemfibrozil 16 27 5785 5796 B-treatment

Known 0 5 5797 5802 O
history 6 13 5803 5810 O
of 14 16 5811 5813 O
hepatitis 17 26 5814 5823 B-chronic_disease
B 27 28 5824 5825 I-chronic_disease
virus 29 34 5826 5831 I-chronic_disease
( 35 36 5832 5833 I-chronic_disease
HBV 36 39 5833 5836 I-chronic_disease
) 39 40 5836 5837 I-chronic_disease
, 40 41 5837 5838 O
or 42 44 5839 5841 O
hepatitis 45 54 5842 5851 B-chronic_disease
C 55 56 5852 5853 I-chronic_disease
virus 57 62 5854 5859 I-chronic_disease
( 63 64 5860 5861 I-chronic_disease
HCV 64 67 5861 5864 I-chronic_disease
) 67 68 5864 5865 I-chronic_disease
infection 69 78 5866 5875 O
( 79 80 5876 5877 O
patients 80 88 5877 5885 O
with 89 93 5886 5890 O
chronic 94 101 5891 5898 O
or 102 104 5899 5901 O
cleared 105 112 5902 5909 O
HBV 113 116 5910 5913 O
and 117 120 5914 5917 O
HCV 121 124 5918 5921 O
infection 125 134 5922 5931 O
are 135 138 5932 5935 O
eligible 139 147 5936 5944 O
) 147 148 5944 5945 O
; 148 149 5945 5946 O
it 150 152 5947 5949 O
is 153 155 5950 5952 O
not 156 159 5953 5956 O
necessary 160 169 5957 5966 O
to 170 172 5967 5969 O
conduct 173 180 5970 5977 O
HBV 181 184 5978 5981 O
and 185 188 5982 5985 O
HCV 189 192 5986 5989 O
testing 193 200 5990 5997 O
at 201 203 5998 6000 O
screening 204 213 6001 6010 O

Left 0 4 6011 6015 B-clinical_variable
ventricular 5 16 6016 6027 I-clinical_variable
ejection 17 25 6028 6036 I-clinical_variable
fraction 26 34 6037 6045 I-clinical_variable
> 35 36 6046 6047 O
= 36 37 6047 6048 O
institutional 38 51 6049 6062 O
lower 52 57 6063 6068 O
limit 58 63 6069 6074 O
of 64 66 6075 6077 O
normal 67 73 6078 6084 O
( 74 75 6085 6086 O
LLN 75 78 6086 6089 O
) 78 79 6089 6090 O
by 80 82 6091 6093 O
echocardiogram 83 97 6094 6108 B-treatment
( 98 99 6109 6110 I-treatment
ECHO 99 103 6110 6114 I-treatment
) 103 104 6114 6115 I-treatment

Leukocytes 0 10 6116 6126 B-clinical_variable
> 11 12 6127 6128 O
= 12 13 6128 6129 O
3,000 14 19 6130 6135 B-lower_bound
/ 19 20 6135 6136 I-lower_bound
mcL 20 23 6136 6139 I-lower_bound

Life 0 4 6140 6144 B-clinical_variable
expectancy 5 15 6145 6155 I-clinical_variable
of 16 18 6156 6158 O
greater 19 26 6159 6166 O
than 27 31 6167 6171 O
3 32 33 6172 6173 B-lower_bound
months 34 40 6174 6180 I-lower_bound

Miscellaneous 0 13 6181 6194 O
: 13 14 6194 6195 O
bosentan 15 23 6196 6204 B-treatment
, 23 24 6204 6205 O
St. 25 28 6206 6209 B-treatment
John 29 33 6210 6214 I-treatment
's 33 35 6214 6216 I-treatment
wort 36 40 6217 6221 I-treatment

Miscellaneous 0 13 6222 6235 O
: 13 14 6235 6236 O
conivaptan 15 25 6237 6247 B-treatment

Other 0 5 6248 6253 O
anti 6 10 6254 6258 B-treatment
- 10 11 6258 6259 I-treatment
cancer 11 17 6259 6265 I-treatment
therapy 18 25 6266 6273 I-treatment
while 26 31 6274 6279 O
on 32 34 6280 6282 O
study 35 40 6283 6288 O
treatment 41 50 6289 6298 B-treatment
; 50 51 6298 6299 O
( 52 53 6300 6301 O
note 53 57 6301 6305 O
: 57 58 6305 6306 O
megestrol 59 68 6307 6316 B-treatment
[ 69 70 6317 6318 I-treatment
Megace 70 76 6318 6324 I-treatment
] 76 77 6324 6325 I-treatment
if 78 80 6326 6328 O
used 81 85 6329 6333 O
as 86 88 6334 6336 O
an 89 91 6337 6339 O
appetite 92 100 6340 6348 O
stimulant 101 110 6349 6358 O
is 111 113 6359 6361 O
allowed 114 121 6362 6369 O
) 121 122 6369 6370 O

Patients 0 8 6371 6379 O
must 9 13 6380 6384 O
have 14 18 6385 6389 O
a 19 20 6390 6391 O
corrected 21 30 6392 6401 O
QT 31 33 6402 6404 B-clinical_variable
( 34 35 6405 6406 I-clinical_variable
QTc 35 38 6406 6409 I-clinical_variable
) 38 39 6409 6410 I-clinical_variable
interval 40 48 6411 6419 I-clinical_variable
of 49 51 6420 6422 O
less 52 56 6423 6427 O
than 57 61 6428 6432 O
480 62 65 6433 6436 B-upper_bound
msec 66 70 6437 6441 I-upper_bound

Patients 0 8 6442 6450 O
must 9 13 6451 6455 O
have 14 18 6456 6460 O
histologically 19 33 6461 6475 O
confirmed 34 43 6476 6485 O
, 43 44 6485 6486 O
BRAF 45 49 6487 6491 O
- 49 50 6491 6492 O
mutant 50 56 6492 6498 O
( 57 58 6499 6500 O
V600E 58 63 6500 6505 O
/ 63 64 6505 6506 O
K 64 65 6506 6507 O
) 65 66 6507 6508 O
melanoma 67 75 6509 6517 B-cancer
( 76 77 6518 6519 O
molecularly 77 88 6519 6530 O
confirmed 89 98 6531 6540 O
using 99 104 6541 6546 O
validated 105 114 6547 6556 O
, 114 115 6556 6557 O
commercially 116 128 6558 6570 O
available 129 138 6571 6580 O
assay 139 144 6581 6586 O
performed 145 154 6587 6596 O
in 155 157 6597 6599 O
a 158 159 6600 6601 O
Clinical 160 168 6602 6610 O
Laboratory 169 179 6611 6621 O
Improvement 180 191 6622 6633 O
Act 192 195 6634 6637 O
[ 196 197 6638 6639 O
CLIA]-approved 197 211 6639 6653 O
laboratory 212 222 6654 6664 O
) 222 223 6664 6665 O
that 224 228 6666 6670 O
is 229 231 6671 6673 O
metastatic 232 242 6674 6684 O
or 243 245 6685 6687 O
unresectable 246 258 6688 6700 O
and 259 262 6701 6704 O
for 263 266 6705 6708 O
which 267 272 6709 6714 O
standard 273 281 6715 6723 O
curative 282 290 6724 6732 O
measures 291 299 6733 6741 O
do 300 302 6742 6744 O
not 303 306 6745 6748 O
exist 307 312 6749 6754 O
or 313 315 6755 6757 O
are 316 319 6758 6761 O
no 320 322 6762 6764 O
longer 323 329 6765 6771 O
effective 330 339 6772 6781 O

Patients 0 8 6782 6790 O
must 9 13 6791 6795 O
have 14 18 6796 6800 O
measurable 19 29 6801 6811 O
disease 30 37 6812 6819 O
, 37 38 6819 6820 O
defined 39 46 6821 6828 O
as 47 49 6829 6831 O
at 50 52 6832 6834 O
least 53 58 6835 6840 O
one 59 62 6841 6844 B-lower_bound
lesion 63 69 6845 6851 O
that 70 74 6852 6856 O
can 75 78 6857 6860 O
be 79 81 6861 6863 O
accurately 82 92 6864 6874 O
measured 93 101 6875 6883 O
in 102 104 6884 6886 O
at 105 107 6887 6889 O
least 108 113 6890 6895 O
one 114 117 6896 6899 O
dimension 118 127 6900 6909 O
( 128 129 6910 6911 O
longest 129 136 6911 6918 O
diameter 137 145 6919 6927 O
to 146 148 6928 6930 O
be 149 151 6931 6933 O
recorded 152 160 6934 6942 O
for 161 164 6943 6946 O
non 165 168 6947 6950 O
- 168 169 6950 6951 O
nodal 169 174 6951 6956 O
lesions 175 182 6957 6964 O
and 183 186 6965 6968 O
short 187 192 6969 6974 O
axis 193 197 6975 6979 O
for 198 201 6980 6983 O
nodal 202 207 6984 6989 O
lesions 208 215 6990 6997 O
) 215 216 6997 6998 O
as 217 219 6999 7001 O
> 220 221 7002 7003 O
= 221 222 7003 7004 O
20 223 225 7005 7007 B-lower_bound
mm 226 228 7008 7010 I-lower_bound
with 229 233 7011 7015 O
conventional 234 246 7016 7028 B-clinical_variable
techniques 247 257 7029 7039 I-clinical_variable
or 258 260 7040 7042 O
as 261 263 7043 7045 O
> 264 265 7046 7047 O
= 265 266 7047 7048 O
10 267 269 7049 7051 B-lower_bound
mm 270 272 7052 7054 I-lower_bound
with 273 277 7055 7059 O
spiral 278 284 7060 7066 O
computed 285 293 7067 7075 B-treatment
tomography 294 304 7076 7086 I-treatment
( 305 306 7087 7088 I-treatment
CT 306 308 7088 7090 I-treatment
) 308 309 7090 7091 I-treatment
scan 310 314 7092 7096 I-treatment
, 314 315 7096 7097 O
magnetic 316 324 7098 7106 B-treatment
resonance 325 334 7107 7116 I-treatment
imaging 335 342 7117 7124 I-treatment
( 343 344 7125 7126 I-treatment
MRI 344 347 7126 7129 I-treatment
) 347 348 7129 7130 I-treatment
, 348 349 7130 7131 O
or 350 352 7132 7134 O
calipers 353 361 7135 7143 B-treatment
by 362 364 7144 7146 O
clinical 365 373 7147 7155 O
exam 374 378 7156 7160 O

Patients 0 8 7161 7169 O
must 9 13 7170 7174 O
not 14 17 7175 7178 O
have 18 22 7179 7183 O
received 23 31 7184 7192 O
prior 32 37 7193 7198 O
navitoclax 38 48 7199 7209 B-treatment
, 48 49 7209 7210 O
unless 50 56 7211 7217 O
the 57 60 7218 7221 O
patient 61 68 7222 7229 O
received 69 77 7230 7238 O
< 78 79 7239 7240 O
7 80 81 7241 7242 B-upper_bound
days 82 86 7243 7247 I-upper_bound
of 87 89 7248 7250 O
navitoclax 90 100 7251 7261 O
lead 101 105 7262 7266 O
- 105 106 7266 7267 O
in 106 108 7267 7269 O
on 109 111 7270 7272 O
this 112 116 7273 7277 O
or 117 119 7278 7280 O
another 120 127 7281 7288 O
study 128 133 7289 7294 O
and 134 137 7295 7298 O
had 138 141 7299 7302 O
to 142 144 7303 7305 O
stop 145 149 7306 7310 O
for 150 153 7311 7314 O
reasons 154 161 7315 7322 O
other 162 167 7323 7328 O
than 168 172 7329 7333 O
toxicity 173 181 7334 7342 O
or 182 184 7343 7345 O
disease 185 192 7346 7353 O
progression 193 204 7354 7365 O

Patients 0 8 7366 7374 O
receiving 9 18 7375 7384 O
any 19 22 7385 7388 O
medications 23 34 7389 7400 B-treatment
or 35 37 7401 7403 O
substances 38 48 7404 7414 O
that 49 53 7415 7419 O
are 54 57 7420 7423 O
strong 58 64 7424 7430 B-treatment
inhibitors 65 75 7431 7441 I-treatment
or 76 78 7442 7444 I-treatment
inducers 79 87 7445 7453 I-treatment
of 88 90 7454 7456 I-treatment
CYP3A 91 96 7457 7462 I-treatment
or 97 99 7463 7465 I-treatment
CYP2C8 100 106 7466 7472 I-treatment
are 107 110 7473 7476 O
ineligible 111 121 7477 7487 O
; 121 122 7487 7488 O
current 123 130 7489 7496 O
use 131 134 7497 7500 O
of 135 137 7501 7503 O
, 137 138 7503 7504 O
or 139 141 7505 7507 O
intended 142 150 7508 7516 O
ongoing 151 158 7517 7524 B-treatment
treatment 159 168 7525 7534 I-treatment
with 169 173 7535 7539 O
: 173 174 7539 7540 O
herbal 175 181 7541 7547 B-treatment
remedies 182 190 7548 7556 I-treatment
( 191 192 7557 7558 O
e.g. 192 196 7558 7562 O
, 196 197 7562 7563 O
St. 198 201 7564 7567 B-treatment
John 202 206 7568 7572 I-treatment
's 206 208 7572 7574 I-treatment
wort 209 213 7575 7579 I-treatment
) 213 214 7579 7580 O
, 214 215 7580 7581 O
or 216 218 7582 7584 O
strong 219 225 7585 7591 B-treatment
inhibitors 226 236 7592 7602 I-treatment
or 237 239 7603 7605 I-treatment
inducers 240 248 7606 7614 I-treatment
of 249 251 7615 7617 I-treatment
permeability 252 264 7618 7630 I-treatment
- 264 265 7630 7631 I-treatment
glycoprotein 265 277 7631 7643 I-treatment
( 278 279 7644 7645 I-treatment
Pgp 279 282 7645 7648 I-treatment
) 282 283 7648 7649 I-treatment
or 284 286 7650 7652 O
breast 287 293 7653 7659 B-treatment
cancer 294 300 7660 7666 I-treatment
resistance 301 311 7667 7677 I-treatment
protein 312 319 7678 7685 I-treatment
1 320 321 7686 7687 I-treatment
( 322 323 7688 7689 I-treatment
Bcrp1 323 328 7689 7694 I-treatment
) 328 329 7694 7695 I-treatment
should 330 336 7696 7702 O
also 337 341 7703 7707 O
be 342 344 7708 7710 O
excluded 345 353 7711 7719 O

Patients 0 8 7720 7728 O
who 9 12 7729 7732 O
are 13 16 7733 7736 O
receiving 17 26 7737 7746 O
any 27 30 7747 7750 O
other 31 36 7751 7756 O
investigational 37 52 7757 7772 B-treatment
agents 53 59 7773 7779 I-treatment
have 60 64 7780 7784 O
received 65 73 7785 7793 O
any 74 77 7794 7797 O
other 78 83 7798 7803 O
investigational 84 99 7804 7819 B-treatment
drugs 100 105 7820 7825 I-treatment
within 106 112 7826 7832 O
28 113 115 7833 7835 B-upper_bound
days 116 120 7836 7840 I-upper_bound
( 121 122 7841 7842 O
or 122 124 7842 7844 O
five 125 129 7845 7849 O
half 130 134 7850 7854 O
- 134 135 7854 7855 O
lives 135 140 7855 7860 O
, 140 141 7860 7861 O
whichever 142 151 7862 7871 O
is 152 154 7872 7874 O
shorter 155 162 7875 7882 O
; 162 163 7882 7883 O
with 164 168 7884 7888 O
a 169 170 7889 7890 O
minimum 171 178 7891 7898 O
of 179 181 7899 7901 O
14 182 184 7902 7904 B-lower_bound
days 185 189 7905 7909 I-lower_bound
from 190 194 7910 7914 O
the 195 198 7915 7918 O
last 199 203 7919 7923 O
dose 204 208 7924 7928 O
) 208 209 7928 7929 O
preceding 210 219 7930 7939 O
the 220 223 7940 7943 O
first 224 229 7944 7949 O
dose 230 234 7950 7954 O
of 235 237 7955 7957 O
study 238 243 7958 7963 O
treatment 244 253 7964 7973 B-treatment
and 254 257 7974 7977 O
during 258 264 7978 7984 O
the 265 268 7985 7988 O
study 269 274 7989 7994 O

Patients 0 8 7995 8003 O
who 9 12 8004 8007 O
have 13 17 8008 8012 O
had 18 21 8013 8016 O
immunotherapy 22 35 8017 8030 B-treatment
, 35 36 8030 8031 O
chemotherapy 37 49 8032 8044 B-treatment
or 50 52 8045 8047 O
radiotherapy 53 65 8048 8060 B-treatment
within 66 72 8061 8067 O
14 73 75 8068 8070 B-upper_bound
days 76 80 8071 8075 I-upper_bound
prior 81 86 8076 8081 I-upper_bound
to 87 89 8082 8084 O
the 90 93 8085 8088 O
first 94 99 8089 8094 O
dose 100 104 8095 8099 O
of 105 107 8100 8102 O
navitoclax 108 118 8103 8113 B-treatment
, 118 119 8113 8114 O
or 120 122 8115 8117 O
prior 123 128 8118 8123 B-treatment
systemic 129 137 8124 8132 I-treatment
anti 138 142 8133 8137 I-treatment
- 142 143 8137 8138 I-treatment
cancer 143 149 8138 8144 I-treatment
therapy 150 157 8145 8152 I-treatment
( 158 159 8153 8154 O
chemotherapy 159 171 8154 8166 O
with 172 176 8167 8171 O
delayed 177 184 8172 8179 O
toxicity 185 193 8180 8188 O
, 193 194 8188 8189 O
extensive 195 204 8190 8199 B-treatment
radiation 205 214 8200 8209 I-treatment
therapy 215 222 8210 8217 I-treatment
, 222 223 8217 8218 O
immunotherapy 224 237 8219 8232 O
, 237 238 8232 8233 O
biologic 239 247 8234 8242 B-treatment
therapy 248 255 8243 8250 I-treatment
, 255 256 8250 8251 O
or 257 259 8252 8254 O
vaccine 260 267 8255 8262 B-treatment
therapy 268 275 8263 8270 I-treatment
) 275 276 8270 8271 O
within 277 283 8272 8278 O
the 284 287 8279 8282 O
last 288 292 8283 8287 B-upper_bound
3 293 294 8288 8289 I-upper_bound
weeks 295 300 8290 8295 I-upper_bound
prior 301 306 8296 8301 I-upper_bound
to 307 309 8302 8304 O
first 310 315 8305 8310 O
dose 316 320 8311 8315 O
of 321 323 8316 8318 O
dabrafenib 324 334 8319 8329 B-treatment
and/or 335 341 8330 8336 O
trametinib 342 352 8337 8347 B-treatment
; 352 353 8347 8348 O
chemotherapy 354 366 8349 8361 B-treatment
regimens 367 375 8362 8370 I-treatment
without 376 383 8371 8378 O
delayed 384 391 8379 8386 O
toxicity 392 400 8387 8395 O
within 401 407 8396 8402 O
the 408 411 8403 8406 O
last 412 416 8407 8411 B-upper_bound
2 417 418 8412 8413 I-upper_bound
weeks 419 424 8414 8419 I-upper_bound
preceding 425 434 8420 8429 O
the 435 438 8430 8433 O
first 439 444 8434 8439 O
dose 445 449 8440 8444 O
of 450 452 8445 8447 O
study 453 458 8448 8453 O
treatment 459 468 8454 8463 B-treatment
; 468 469 8463 8464 O
biologics 470 479 8465 8474 B-treatment
will 480 484 8475 8479 O
not 485 488 8480 8483 O
be 489 491 8484 8486 O
allowed 492 499 8487 8494 O
within 500 506 8495 8501 O
30 507 509 8502 8504 B-upper_bound
days 510 514 8505 8509 I-upper_bound
prior 515 520 8510 8515 I-upper_bound
to 521 523 8516 8518 O
, 523 524 8518 8519 O
or 525 527 8520 8522 O
during 528 534 8523 8529 O
, 534 535 8529 8530 O
navitoclax 536 546 8531 8541 O
administration 547 561 8542 8556 O

Platelets 0 9 8557 8566 B-clinical_variable
> 10 11 8567 8568 O
= 11 12 8568 8569 O
100,000 13 20 8570 8577 B-lower_bound
/ 20 21 8577 8578 I-lower_bound
mcL 21 24 8578 8581 I-lower_bound

Preclinical 0 11 8582 8593 O
studies 12 19 8594 8601 O
indicate 20 28 8602 8610 O
that 29 33 8611 8615 O
navitoclax 34 44 8616 8626 B-treatment
is 45 47 8627 8629 O
metabolized 48 59 8630 8641 O
by 60 62 8642 8644 O
CYP3A4 63 69 8645 8651 B-treatment
, 69 70 8651 8652 O
is 71 73 8653 8655 O
a 74 75 8656 8657 O
moderate 76 84 8658 8666 B-treatment
inhibitor 85 94 8667 8676 I-treatment
of 95 97 8677 8679 I-treatment
CYP2C8 98 104 8680 8686 I-treatment
, 104 105 8686 8687 O
and 106 109 8688 8691 O
is 110 112 8692 8694 O
a 113 114 8695 8696 O
strong 115 121 8697 8703 B-treatment
inhibitor 122 131 8704 8713 I-treatment
of 132 134 8714 8716 I-treatment
CYP2C9 135 141 8717 8723 I-treatment
; 141 142 8723 8724 O
there 143 148 8725 8730 O
is 149 151 8731 8733 O
also 152 156 8734 8738 O
evidence 157 165 8739 8747 O
of 166 168 8748 8750 O
interactions 169 181 8751 8763 O
with 182 186 8764 8768 O
dabrafenib 187 197 8769 8779 B-treatment
; 197 198 8779 8780 O
therefore 199 208 8781 8790 O
, 208 209 8790 8791 O
caution 210 217 8792 8799 O
should 218 224 8800 8806 O
be 225 227 8807 8809 O
exercised 228 237 8810 8819 O
when 238 242 8820 8824 O
dosing 243 249 8825 8831 O
navitoclax 250 260 8832 8842 B-treatment
concurrently 261 273 8843 8855 I-treatment
with 274 278 8856 8860 I-treatment
CYP2C8 279 285 8861 8867 I-treatment
and 286 289 8868 8871 I-treatment
CYP2C9 290 296 8872 8878 I-treatment
substrates 297 307 8879 8889 I-treatment
; 307 308 8889 8890 O
common 309 315 8891 8897 O
CYP2C8 316 322 8898 8904 B-treatment
substrates 323 333 8905 8915 I-treatment
include 334 341 8916 8923 O
paclitaxel 342 352 8924 8934 B-treatment
, 352 353 8934 8935 O
statins 354 361 8936 8943 B-treatment
, 361 362 8943 8944 O
and 363 366 8945 8948 O
glitazones 367 377 8949 8959 B-treatment
, 377 378 8959 8960 O
whereas 379 386 8961 8968 O
CYP2C9 387 393 8969 8975 B-treatment
substrates 394 404 8976 8986 I-treatment
include 405 412 8987 8994 I-treatment
phenytoin 413 422 8995 9004 I-treatment
; 422 423 9004 9005 O
when 424 428 9006 9010 O
possible 429 437 9011 9019 O
, 437 438 9019 9020 O
investigators 439 452 9021 9034 O
should 453 459 9035 9041 O
switch 460 466 9042 9048 O
to 467 469 9049 9051 O
alternative 470 481 9052 9063 O
medications 482 493 9064 9075 B-treatment
or 494 496 9076 9078 O
monitor 497 504 9079 9086 O
the 505 508 9087 9090 O
patients 509 517 9091 9099 O
closely 518 525 9100 9107 O
; 525 526 9107 9108 O
CYP3A 527 532 9109 9114 B-treatment
inhibitors 533 543 9115 9125 I-treatment
such 544 548 9126 9130 I-treatment
as 549 551 9131 9133 I-treatment
ketoconazole 552 564 9134 9146 I-treatment
and 565 568 9147 9150 I-treatment
clarithromycin 569 583 9151 9165 I-treatment
are 584 587 9166 9169 O
not 588 591 9170 9173 O
allowed 592 599 9174 9181 O
7 600 601 9182 9183 B-upper_bound
days 602 606 9184 9188 I-upper_bound
prior 607 612 9189 9194 I-upper_bound
to 613 615 9195 9197 O
the 616 619 9198 9201 O
first 620 625 9202 9207 B-treatment
dose 626 630 9208 9212 I-treatment
of 631 633 9213 9215 I-treatment
navitoclax 634 644 9216 9226 I-treatment
or 645 647 9227 9229 O
during 648 654 9230 9236 O
navitoclax 655 665 9237 9247 O
administration 666 680 9248 9262 O

Pregnant 0 8 9263 9271 B-pregnancy
women 9 14 9272 9277 B-gender
are 15 18 9278 9281 O
excluded 19 27 9282 9290 O
from 28 32 9291 9295 O
this 33 37 9296 9300 O
study 38 43 9301 9306 O
because 44 51 9307 9314 O
navitoclax 52 62 9315 9325 B-treatment
, 62 63 9325 9326 O
dabrafenib 64 74 9327 9337 B-treatment
, 74 75 9337 9338 O
and 76 79 9339 9342 O
trametinib 80 90 9343 9353 B-treatment
may 91 94 9354 9357 O
have 95 99 9358 9362 O
teratogenic 100 111 9363 9374 O
or 112 114 9375 9377 O
abortifacient 115 128 9378 9391 O
effects 129 136 9392 9399 O
; 136 137 9399 9400 O
because 138 145 9401 9408 O
there 146 151 9409 9414 O
is 152 154 9415 9417 O
an 155 157 9418 9420 O
unknown 158 165 9421 9428 O
but 166 169 9429 9432 O
potential 170 179 9433 9442 O
risk 180 184 9443 9447 O
for 185 188 9448 9451 O
adverse 189 196 9452 9459 O
events 197 203 9460 9466 O
in 204 206 9467 9469 O
nursing 207 214 9470 9477 O
infants 215 222 9478 9485 O
secondary 223 232 9486 9495 O
to 233 235 9496 9498 O
treatment 236 245 9499 9508 B-treatment
of 246 248 9509 9511 O
the 249 252 9512 9515 O
mother 253 259 9516 9522 O
with 260 264 9523 9527 O
the 265 268 9528 9531 O
study 269 274 9532 9537 B-treatment
drugs 275 280 9538 9543 I-treatment
, 280 281 9543 9544 O
breastfeeding 282 295 9545 9558 O
should 296 302 9559 9565 O
be 303 305 9566 9568 O
discontinued 306 318 9569 9581 O
if 319 321 9582 9584 O
the 322 325 9585 9588 O
mother 326 332 9589 9595 O
is 333 335 9596 9598 O
treated 336 343 9599 9606 O
with 344 348 9607 9611 O
the 349 352 9612 9615 O
study 353 358 9616 9621 O
drugs 359 364 9622 9627 O

Prior 0 5 9628 9633 B-treatment
navitoclax 6 16 9634 9644 I-treatment
, 16 17 9644 9645 O
BRAF 18 22 9646 9650 B-treatment
inhibitor 23 32 9651 9660 I-treatment
, 32 33 9660 9661 O
and 34 37 9662 9665 O
MEK 38 41 9666 9669 B-treatment
inhibitor 42 51 9670 9679 I-treatment
is 52 54 9680 9682 O
prohibited 55 65 9683 9693 O
; 65 66 9693 9694 O
( 67 68 9695 9696 O
exceptions 68 78 9696 9706 O
for 79 82 9707 9710 O
Phase 83 88 9711 9716 O
I 89 90 9717 9718 O
are 91 94 9719 9722 O
described 95 104 9723 9732 O
above 105 110 9733 9738 O
) 110 111 9738 9739 O

Prior 0 5 9740 9745 B-treatment
therapy 6 13 9746 9753 I-treatment
is 14 16 9754 9756 O
allowed 17 24 9757 9764 O
; 24 25 9764 9765 O
for 26 29 9766 9769 O
patients 30 38 9770 9778 O
enrolled 39 47 9779 9787 O
in 48 50 9788 9790 O
the 51 54 9791 9794 O
Phase 55 60 9795 9800 O
I 61 62 9801 9802 O
portion 63 70 9803 9810 O
of 71 73 9811 9813 O
the 74 77 9814 9817 O
study 78 83 9818 9823 O
, 83 84 9823 9824 O
patients 85 93 9825 9833 O
may 94 97 9834 9837 O
have 98 102 9838 9842 O
received 103 111 9843 9851 O
any 112 115 9852 9855 O
number 116 122 9856 9862 O
of 123 125 9863 9865 O
prior 126 131 9866 9871 O
lines 132 137 9872 9877 O
of 138 140 9878 9880 O
therapy 141 148 9881 9888 O
including 149 158 9889 9898 O
treatment 159 168 9899 9908 B-treatment
with 169 173 9909 9913 I-treatment
a 174 175 9914 9915 I-treatment
BRAF 176 180 9916 9920 I-treatment
and/or 181 187 9921 9927 O
MEK 188 191 9928 9931 B-treatment
inhibitor 192 201 9932 9941 I-treatment
; 201 202 9941 9942 O
prior 203 208 9943 9948 B-treatment
navitoclax 209 219 9949 9959 I-treatment
use 220 223 9960 9963 O
will 224 228 9964 9968 O
not 229 232 9969 9972 O
be 233 235 9973 9975 O
allowed 236 243 9976 9983 O
, 243 244 9983 9984 O
unless 245 251 9985 9991 O
the 252 255 9992 9995 O
patient 256 263 9996 10003 O
received 264 272 10004 10012 O
< 273 274 10013 10014 O
7 275 276 10015 10016 B-upper_bound
days 277 281 10017 10021 I-upper_bound
of 282 284 10022 10024 O
navitoclax 285 295 10025 10035 O
lead 296 300 10036 10040 O
- 300 301 10040 10041 O
in 301 303 10041 10043 O
on 304 306 10044 10046 O
this 307 311 10047 10051 O
or 312 314 10052 10054 O
another 315 322 10055 10062 O
study 323 328 10063 10068 O
and 329 332 10069 10072 O
had 333 336 10073 10076 O
to 337 339 10077 10079 O
stop 340 344 10080 10084 O
for 345 348 10085 10088 O
reasons 349 356 10089 10096 O
other 357 362 10097 10102 O
than 363 367 10103 10107 O
toxicity 368 376 10108 10116 O
or 377 379 10117 10119 O
disease 380 387 10120 10127 O
progression 388 399 10128 10139 O

Prior 0 5 10140 10145 B-treatment
therapy 6 13 10146 10153 I-treatment
is 14 16 10154 10156 O
allowed 17 24 10157 10164 O
; 24 25 10164 10165 O
for 26 29 10166 10169 O
patients 30 38 10170 10178 O
enrolled 39 47 10179 10187 O
in 48 50 10188 10190 O
the 51 54 10191 10194 O
Phase 55 60 10195 10200 O
II 61 63 10201 10203 O
portion 64 71 10204 10211 O
of 72 74 10212 10214 O
the 75 78 10215 10218 O
study 79 84 10219 10224 O
, 84 85 10224 10225 O
patients 86 94 10226 10234 O
may 95 98 10235 10238 O
have 99 103 10239 10243 O
received 104 112 10244 10252 O
prior 113 118 10253 10258 B-treatment
immunotherapy 119 132 10259 10272 I-treatment
( 133 134 10273 10274 O
including 134 143 10274 10283 O
high 144 148 10284 10288 B-treatment
- 148 149 10288 10289 I-treatment
dose 149 153 10289 10293 I-treatment
IL-2 154 158 10294 10298 I-treatment
, 158 159 10298 10299 O
ipilimumab 160 170 10300 10310 B-treatment
, 170 171 10310 10311 O
nivolumab 172 181 10312 10321 B-treatment
, 181 182 10321 10322 O
and 183 186 10323 10326 O
other 187 192 10327 10332 O
anti 193 197 10333 10337 B-treatment
- 197 198 10337 10338 I-treatment
PD1 198 201 10338 10341 I-treatment
/ 201 202 10341 10342 I-treatment
PDL1 202 206 10342 10346 I-treatment
antibodies 207 217 10347 10357 I-treatment
) 217 218 10357 10358 O
or 219 221 10359 10361 O
chemotherapy 222 234 10362 10374 B-treatment
; 234 235 10374 10375 O
however 236 243 10376 10383 O
prior 244 249 10384 10389 B-treatment
navitoclax 250 260 10390 10400 I-treatment
, 260 261 10400 10401 O
BRAF 262 266 10402 10406 B-treatment
inhibitor 267 276 10407 10416 I-treatment
and/or 277 283 10417 10423 O
MEK 284 287 10424 10427 B-treatment
inhibitor 288 297 10428 10437 I-treatment
therapy 298 305 10438 10445 I-treatment
will 306 310 10446 10450 O
not 311 314 10451 10454 O
be 315 317 10455 10457 O
allowed 318 325 10458 10465 O

Prothrombin 0 11 10466 10477 B-clinical_variable
time 12 16 10478 10482 I-clinical_variable
( 17 18 10483 10484 I-clinical_variable
PT)/international 18 35 10484 10501 I-clinical_variable
normalized 36 46 10502 10512 I-clinical_variable
ratio 47 52 10513 10518 I-clinical_variable
( 53 54 10519 10520 I-clinical_variable
INR 54 57 10520 10523 I-clinical_variable
) 57 58 10523 10524 I-clinical_variable
and 59 62 10525 10528 O
partial 63 70 10529 10536 B-clinical_variable
thromboplastin 71 85 10537 10551 I-clinical_variable
time 86 90 10552 10556 I-clinical_variable
( 91 92 10557 10558 I-clinical_variable
PTT 92 95 10558 10561 I-clinical_variable
) 95 96 10561 10562 I-clinical_variable
< 97 98 10563 10564 O
1.3 99 102 10565 10568 B-upper_bound
x 103 104 10569 10570 I-upper_bound
upper 105 110 10571 10576 I-upper_bound
limit 111 116 10577 10582 I-upper_bound
of 117 119 10583 10585 I-upper_bound
normal 120 126 10586 10592 I-upper_bound
( 127 128 10593 10594 I-upper_bound
ULN 128 131 10594 10597 I-upper_bound
) 131 132 10597 10598 I-upper_bound

Serum 0 5 10599 10604 B-clinical_variable
creatinine 6 16 10605 10615 I-clinical_variable
= 17 18 10616 10617 O
< 18 19 10617 10618 O
1.5 20 23 10619 10622 B-upper_bound
mg 24 26 10623 10625 I-upper_bound
/ 26 27 10625 10626 I-upper_bound
dL 27 29 10626 10628 I-upper_bound
OR 30 32 10629 10631 O
creatinine 33 43 10632 10642 B-clinical_variable
clearance 44 53 10643 10652 I-clinical_variable
> 54 55 10653 10654 O
= 55 56 10654 10655 O
50 57 59 10656 10658 B-lower_bound
mL 60 62 10659 10661 I-lower_bound
/ 62 63 10661 10662 I-lower_bound
min/1.73 63 71 10662 10670 I-lower_bound
m^2 72 75 10671 10674 I-lower_bound

Strong 0 6 10675 10681 B-treatment
inducers 7 15 10682 10690 I-treatment
of 16 18 10691 10693 I-treatment
CYP3A 19 24 10694 10699 I-treatment
or 25 27 10700 10702 O
CYP2C8 28 34 10703 10709 B-treatment

Strong 0 6 10710 10716 B-treatment
inhibitors 7 17 10717 10727 I-treatment
of 18 20 10728 10730 I-treatment
CYP3A 21 26 10731 10736 I-treatment
or 27 29 10737 10739 I-treatment
CYP2C8 30 36 10740 10746 I-treatment

Subject 0 7 10747 10754 O
has 8 11 10755 10758 O
a 12 13 10759 10760 O
recent 14 20 10761 10767 O
history 21 28 10768 10775 O
of 29 31 10776 10778 O
non 32 35 10779 10782 B-treatment
- 35 36 10782 10783 I-treatment
chemotherapy 36 48 10783 10795 I-treatment
- 48 49 10795 10796 O
induced 49 56 10796 10803 O
thrombocytopenic 57 73 10804 10820 B-chronic_disease
- 73 74 10820 10821 O
associated 74 84 10821 10831 O
bleeding 85 93 10832 10840 O
within 94 100 10841 10847 O
1 101 102 10848 10849 B-upper_bound
year 103 107 10850 10854 I-upper_bound
prior 108 113 10855 10860 I-upper_bound
to 114 116 10861 10863 O
the 117 120 10864 10867 O
first 121 126 10868 10873 O
dose 127 131 10874 10878 O
of 132 134 10879 10881 O
study 135 140 10882 10887 O
drug 141 145 10888 10892 O

The 0 3 10893 10896 O
effects 4 11 10897 10904 O
of 12 14 10905 10907 O
navitoclax 15 25 10908 10918 B-treatment
, 25 26 10918 10919 O
dabrafenib 27 37 10920 10930 B-treatment
, 37 38 10930 10931 O
and 39 42 10932 10935 O
trametinib 43 53 10936 10946 B-treatment
on 54 56 10947 10949 O
the 57 60 10950 10953 O
developing 61 71 10954 10964 O
human 72 77 10965 10970 O
fetus 78 83 10971 10976 O
are 84 87 10977 10980 O
unknown 88 95 10981 10988 O
; 95 96 10988 10989 O
for 97 100 10990 10993 O
this 101 105 10994 10998 O
reason 106 112 10999 11005 O
, 112 113 11005 11006 O
women 114 119 11007 11012 B-gender
of 120 122 11013 11015 O
child 123 128 11016 11021 O
- 128 129 11021 11022 O
bearing 129 136 11022 11029 O
potential 137 146 11030 11039 O
and 147 150 11040 11043 O
men 151 154 11044 11047 O
with 155 159 11048 11052 O
partners 160 168 11053 11061 O
of 169 171 11062 11064 O
childbearing 172 184 11065 11077 O
potential 185 194 11078 11087 O
must 195 199 11088 11092 O
agree 200 205 11093 11098 B-contraception_consent
to 206 208 11099 11101 I-contraception_consent
use 209 212 11102 11105 I-contraception_consent
adequate 213 221 11106 11114 I-contraception_consent
contraception 222 235 11115 11128 I-contraception_consent
( 236 237 11129 11130 O
barrier 237 244 11130 11137 B-contraception_consent
method 245 251 11138 11144 I-contraception_consent
of 252 254 11145 11147 I-contraception_consent
birth 255 260 11148 11153 I-contraception_consent
control 261 268 11154 11161 I-contraception_consent
, 268 269 11161 11162 O
or 270 272 11163 11165 O
abstinence 273 283 11166 11176 B-contraception_consent
; 283 284 11176 11177 O
hormonal 285 293 11178 11186 B-contraception_consent
contraception 294 307 11187 11200 I-contraception_consent
is 308 310 11201 11203 O
not 311 314 11204 11207 O
allowed 315 322 11208 11215 O
due 323 326 11216 11219 O
to 327 329 11220 11222 O
drug 330 334 11223 11227 O
- 334 335 11227 11228 O
drug 335 339 11228 11232 O
interactions 340 352 11233 11245 O
which 353 358 11246 11251 O
can 359 362 11252 11255 O
render 363 369 11256 11262 O
hormonal 370 378 11263 11271 O
contraceptives 379 393 11272 11286 O
ineffective 394 405 11287 11298 O
) 405 406 11298 11299 O
prior 407 412 11300 11305 O
to 413 415 11306 11308 O
study 416 421 11309 11314 O
entry 422 427 11315 11320 O
, 427 428 11320 11321 O
for 429 432 11322 11325 O
the 433 436 11326 11329 O
duration 437 445 11330 11338 O
of 446 448 11339 11341 O
study 449 454 11342 11347 O
participation 455 468 11348 11361 O
, 468 469 11361 11362 O
and 470 473 11363 11366 O
for 474 477 11367 11370 O
4 478 479 11371 11372 B-upper_bound
months 480 486 11373 11379 I-upper_bound
after 487 492 11380 11385 I-upper_bound
completion 493 503 11386 11396 O
of 504 506 11397 11399 O
study 507 512 11400 11405 O
drug 513 517 11406 11410 O
administration 518 532 11411 11425 O
; 532 533 11425 11426 O
should 534 540 11427 11433 O
a 541 542 11434 11435 O
woman 543 548 11436 11441 B-gender
become 549 555 11442 11448 B-pregnancy
pregnant 556 564 11449 11457 I-pregnancy
or 565 567 11458 11460 O
suspect 568 575 11461 11468 O
she 576 579 11469 11472 O
is 580 582 11473 11475 O
pregnant 583 591 11476 11484 O
while 592 597 11485 11490 O
she 598 601 11491 11494 O
is 602 604 11495 11497 O
participating 605 618 11498 11511 O
in 619 621 11512 11514 O
this 622 626 11515 11519 O
study 627 632 11520 11525 O
, 632 633 11525 11526 O
she 634 637 11527 11530 O
should 638 644 11531 11537 O
inform 645 651 11538 11544 O
her 652 655 11545 11548 O
treating 656 664 11549 11557 O
physician 665 674 11558 11567 O
immediately 675 686 11568 11579 O

Total 0 5 11580 11585 B-clinical_variable
bilirubin 6 15 11586 11595 I-clinical_variable
= 16 17 11596 11597 O
< 17 18 11597 11598 O
1.5 19 22 11599 11602 O
x 23 24 11603 11604 O
institutional 25 38 11605 11618 O
upper 39 44 11619 11624 O
limit 45 50 11625 11630 O
of 51 53 11631 11633 O
normal 54 60 11634 11640 O
OR 61 63 11641 11643 O
> 64 65 11644 11645 O
1.5 66 69 11646 11649 O
x 70 71 11650 11651 O
institutional 72 85 11652 11665 O
upper 86 91 11666 11671 O
limit 92 97 11672 11677 O
of 98 100 11678 11680 O
normal 101 107 11681 11687 O
allowed 108 115 11688 11695 O
if 116 118 11696 11698 O
direct 119 125 11699 11705 B-clinical_variable
bilirubin 126 135 11706 11715 I-clinical_variable
is 136 138 11716 11718 O
within 139 145 11719 11725 O
normal 146 152 11726 11732 O
range 153 158 11733 11738 O

Treatment 0 9 11739 11748 B-treatment
- 9 10 11748 11749 I-treatment
refractory 10 20 11749 11759 I-treatment
hypertension 21 33 11760 11772 I-treatment
defined 34 41 11773 11780 O
as 42 44 11781 11783 O
a 45 46 11784 11785 O
blood 47 52 11786 11791 B-clinical_variable
pressure 53 61 11792 11800 I-clinical_variable
of 62 64 11801 11803 I-clinical_variable
systolic 65 73 11804 11812 I-clinical_variable
> 74 75 11813 11814 O
140 76 79 11815 11818 B-lower_bound
mmHg 80 84 11819 11823 I-lower_bound
and/or 85 91 11824 11830 O
diastolic 92 101 11831 11840 B-clinical_variable
> 102 103 11841 11842 O
90 104 106 11843 11845 B-lower_bound
mmHg 107 111 11846 11850 I-lower_bound
which 112 117 11851 11856 O
can 118 121 11857 11860 O
not 121 124 11860 11863 O
be 125 127 11864 11866 O
controlled 128 138 11867 11877 O
by 139 141 11878 11880 O
anti 142 146 11881 11885 B-treatment
- 146 147 11885 11886 I-treatment
hypertensive 147 159 11886 11898 I-treatment
therapy 160 167 11899 11906 I-treatment

Uncontrolled 0 12 11907 11919 O
intercurrent 13 25 11920 11932 B-chronic_disease
illness 26 33 11933 11940 I-chronic_disease
including 34 43 11941 11950 O
, 43 44 11950 11951 O
but 45 48 11952 11955 O
not 49 52 11956 11959 O
limited 53 60 11960 11967 O
to 61 63 11968 11970 O
, 63 64 11970 11971 O
ongoing 65 72 11972 11979 O
or 73 75 11980 11982 O
active 76 82 11983 11989 B-chronic_disease
serious 83 90 11990 11997 I-chronic_disease
infection 91 100 11998 12007 I-chronic_disease
, 100 101 12007 12008 O
symptomatic 102 113 12009 12020 O
congestive 114 124 12021 12031 B-chronic_disease
heart 125 130 12032 12037 I-chronic_disease
failure 131 138 12038 12045 I-chronic_disease
, 138 139 12045 12046 O
unstable 140 148 12047 12055 B-chronic_disease
angina 149 155 12056 12062 I-chronic_disease
pectoris 156 164 12063 12071 I-chronic_disease
, 164 165 12071 12072 O
cardiac 166 173 12073 12080 B-chronic_disease
arrhythmia 174 184 12081 12091 I-chronic_disease
, 184 185 12091 12092 O
uncontrolled 186 198 12093 12105 B-chronic_disease
diabetes 199 207 12106 12114 I-chronic_disease
, 207 208 12114 12115 O
or 209 211 12116 12118 O
psychiatric 212 223 12119 12130 B-chronic_disease
illness 224 231 12131 12138 I-chronic_disease
/ 231 232 12138 12139 O
social 232 238 12139 12145 B-chronic_disease
situations 239 249 12146 12156 I-chronic_disease
that 250 254 12157 12161 O
would 255 260 12162 12167 O
limit 261 266 12168 12173 O
compliance 267 277 12174 12184 O
with 278 282 12185 12189 O
study 283 288 12190 12195 O
requirements 289 301 12196 12208 O

Unresolved 0 10 12209 12219 O
toxicity 11 19 12220 12228 O
of 20 22 12229 12231 O
National 23 31 12232 12240 O
Cancer 32 38 12241 12247 O
Institute 39 48 12248 12257 O
Common 49 55 12258 12264 O
Terminology 56 67 12265 12276 O
Criteria 68 76 12277 12285 O
for 77 80 12286 12289 O
Adverse 81 88 12290 12297 O
Events 89 95 12298 12304 O
, 95 96 12304 12305 O
version 97 104 12306 12313 O
5.0 105 108 12314 12317 O
( 109 110 12318 12319 O
NCI 110 113 12319 12322 O
CTCAE 114 119 12323 12328 O
v. 120 122 12329 12331 O
5.0 123 126 12332 12335 O
) 126 127 12335 12336 O
grade 128 133 12337 12342 B-lower_bound
2 134 135 12343 12344 I-lower_bound
or 136 138 12345 12347 O
higher 139 145 12348 12354 O
from 146 150 12355 12359 O
previous 151 159 12360 12368 B-treatment
anti 160 164 12369 12373 I-treatment
- 164 165 12373 12374 I-treatment
cancer 165 171 12374 12380 I-treatment
therapy 172 179 12381 12388 I-treatment
, 179 180 12388 12389 O
except 181 187 12390 12396 O
alopecia 188 196 12397 12405 B-chronic_disease
or 197 199 12406 12408 O
an 200 202 12409 12411 O
endocrine 203 212 12412 12421 O
toxicity 213 221 12422 12430 O
related 222 229 12431 12438 O
to 230 232 12439 12441 O
immunotherapy 233 246 12442 12455 B-treatment
( 247 248 12456 12457 O
e.g. 248 252 12457 12461 O
thyroiditis 253 264 12462 12473 B-chronic_disease
/ 264 265 12473 12474 O
hypothyroidism 265 279 12474 12488 B-chronic_disease
, 279 280 12488 12489 O
adrenal 281 288 12490 12497 B-chronic_disease
insufficiency 289 302 12498 12511 I-chronic_disease
, 302 303 12511 12512 O
hypophysitis 304 316 12513 12525 B-chronic_disease
) 316 317 12525 12526 O
requiring 318 327 12527 12536 O
replacement 328 339 12537 12548 B-treatment
therapy 340 347 12549 12556 I-treatment
, 347 348 12556 12557 O
at 349 351 12558 12560 O
the 352 355 12561 12564 O
time 356 360 12565 12569 O
of 361 363 12570 12572 O
randomization 364 377 12573 12586 O

Visible 0 7 12587 12594 O
retinal 8 15 12595 12602 O
pathology 16 25 12603 12612 O
as 26 28 12613 12615 O
assessed 29 37 12616 12624 O
by 38 40 12625 12627 O
ophthalmic 41 51 12628 12638 O
exam 52 56 12639 12643 O
that 57 61 12644 12648 O
is 62 64 12649 12651 O
considered 65 75 12652 12662 O
a 76 77 12663 12664 O
risk 78 82 12665 12669 O
factor 83 89 12670 12676 O
for 90 93 12677 12680 O
RVO 94 97 12681 12684 B-chronic_disease
or 98 100 12685 12687 O
CSR 101 104 12688 12691 B-chronic_disease
such 105 109 12692 12696 O
as 110 112 12697 12699 O
evidence 113 121 12700 12708 O
of 122 124 12709 12711 O
new 125 128 12712 12715 O
optic 129 134 12716 12721 O
disc 135 139 12722 12726 O
cupping 140 147 12727 12734 O
, 147 148 12734 12735 O
evidence 149 157 12736 12744 O
of 158 160 12745 12747 O
new 161 164 12748 12751 O
visual 165 171 12752 12758 O
field 172 177 12759 12764 O
defects 178 185 12765 12772 O
, 185 186 12772 12773 O
and 187 190 12774 12777 O
intraocular 191 202 12778 12789 B-clinical_variable
pressure 203 211 12790 12798 I-clinical_variable
> 212 213 12799 12800 O
21 214 216 12801 12803 B-lower_bound
mmHg 217 221 12804 12808 I-lower_bound

